Skip to content

Multicenter prospective single-group study of three-day regimen of oseltamivir (Tamiflu) for postexposure prophylaxis.

Multicenter prospective single-group study of three-day regimen of oseltamivir (Tamiflu) for postexposure prophylaxis. - Three-day regimen of oseltamivir for postexposure prophylaxis.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000024458
Enrollment
279
Registered
2016-10-31
Start date
2016-11-09
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Individuals who shared a room with the index patient infected with influenza.

Interventions

Individuals who shared a room with the influenza patient with a positive immuno-chromatographic test were given oseltamivir for three days as post-exposure prophylaxis.

Sponsors

Hokkaido University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patiets older than one year of age. 2. Individuals who shared a room with influenza patient (index case) with a positive immuno-chromatographic test were immediately separated from the index case by transferring to isolation room. 3. Oseltamivir for post-exposure prophylaxis was started within 48 hours after the onset of fever in the index case. 4. Written informed consent was obtained from each patient before enrolment.

Exclusion criteria

Exclusion criteria: 1. Patients with renal insufficiency (creatinine clearance less than 30 mL/min). 2. Patients older than 10 years and younger than 20 years. 3. Any other patients who are regarded as unsuitable for this study by the investigator.

Design outcomes

Primary

MeasureTime frame
Primary outcome of this study is occurrence of influenza infection after a three-day regimen of oseltamivir as postexposure prophylaxis. Individuals who shared a room with the index patient infected with influenza were monitored for influenza-like symptoms for seven days after postexposure prophylaxis.

Countries

Japan

Contacts

Public ContactNobuhisa Ishiguro

Hokkaido University Hospital Infection Control Team

nishigur@med.hokudai.ac.jp011-706-5703

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026